Glenmark Ichnos drug shows promise against multiple myeloma but can it beat Big Pharma

Early results hint at a cheaper cancer contender

Glenmark’s Ichnos drug is showing promising results for multiple myeloma, a rare blood cancer, raising hopes for affordable breakthrough therapy. With the global market for such drugs projected to reach about USD 30 billion by decade’s end, the question is whether early clinical signals can translate into scale and pricing power against global heavyweights like J&J, Gilead, and Sanofi.